India Generic Giant Lupin to Bid on GSK's Mature Drugs
Mumbai-based generic drugmaker Lupin is planning to bid for GSK's portfolio of older drugs, says sources at Reuters India.
According to Reuters sources, Lupin, as well as some U.S. drugmakers, are looking for a tax-saving deal in Europe through the GSK auction. Lupin has previously expressed interest in enhancing its branded generics business in the United States.
GSK CEO Andrew Witty had announced the review of GSK's established products in April, opening the bidding in May. GSK plans to sell the rights to established products in North America and Western Europe, but retain them in emerging markets and Japan.